Lung cancer in 2014: optimizing lung cancer treatment approaches

Rafael Rosell; Niki Karachaliou

doi:10.1038/nrclinonc.2014.225

Lung cancer in 2014: optimizing lung cancer treatment approaches

Nat Rev Clin Oncol. 2015 Feb;12(2):75-6. doi: 10.1038/nrclinonc.2014.225. Epub 2014 Dec 23.

Authors

Rafael Rosell¹, Niki Karachaliou²

Affiliations

¹ Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Carretera Canyet s/n, 08916 Badalona, Barcelona, Spain.
² Fundación Molecular Oncology Research (MORe), Quirón Dexeus University Hospital, Sabino Arana 5-19, 08028 Barcelona, Spain.

PMID: 25533943
DOI: 10.1038/nrclinonc.2014.225

Abstract

In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Genes, erbB-1 / genetics
Humans
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Molecular Targeted Therapy / methods
Mutation
Positron-Emission Tomography